C12N 2760/12034
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/12034 (Use of virus or viral component as vaccine) appears on 26 US grants and 44 published applications in this corpus.
Search patents in C12N- Granted patents
- 26
- Published applications
- 44
- Assignees
- 34
- Inventors
- 109
- Latest grant
- 17 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 3 |
| 2012 | 1 | 1 |
| 2013 | 0 | 3 |
| 2014 | 0 | 3 |
| 2015 | 2 | 2 |
| 2016 | 3 | 4 |
| 2017 | 4 | 0 |
| 2018 | 3 | 3 |
| 2019 | 1 | 2 |
| 2020 | 2 | 2 |
| 2021 | 0 | 6 |
| 2022 | 2 | 2 |
| 2023 | 3 | 2 |
| 2024 | 1 | 2 |
| 2025 | 2 | 7 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Crimean-Congo hemorrhagic fever virus M-segment nucleic acid vaccine and methods of use and production17 Mar 2026US 12,576,145 B2The Government of the United States, as represented by the Secretary of the Army
- Severe fever with thrombocytopenia syndrome virus9 Sep 2025US 12,409,216 B2I.D.Bio.
- Bunyavirales vaccine26 Aug 2025US 12,397,048 B2CureVac AG
- Mammal-specific growth-defective arbovirus24 Sep 2024US 12,098,393 B2TenGen Biomedical Company
- Severe fever with thrombocytopenia syndrome virus29 Aug 2023US 11,738,078 B2I.D.Bio.
- Bunyavirales vaccine2 Apr 2026US 2026/0091101 A1CureVac AG
- Crimean-congo hemorrhagic fever virus replicon particles and use thereof15 Jan 2026US 2026/0014243 A1The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Mrna vaccine for bandavirus dabieense and preparation method thereof6 Nov 2025US 2025/0339507 A1Nanjing Medical University
- GP38-Targeting Monoclonal Antibodies Protect Adult Mice Against Lethal Crimean-Congo Hemorrhagic Fever Virus Infection30 Oct 2025US 2025/0333451 A1The Government of the United States, as represented by the Secretary of the Army
- Replicon Compositions and Methods of Using Same for the Treatment of Diseases11 Sep 2025US 2025/0281602 A1BioNTech SE
Most cited
By later US patents
- Bunyavirales vaccine9US 11,602,557 B2Cure Vac SE · 2023
- Method of attenuating viruses with simultaneous stabilization of their antigens using selected aminomethylol compounds6US 3,981,772 A1976
- Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae4US 8,298,541 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2012
- Methods to produce bunyavirus replicon particles4US 9,109,199 B2Stichting Dienst Landbouwkundig Onderzoek · 2015
- Live attenuated virus vaccines for la crosse virus and other bunyaviridae3US 9,884,104 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2018